Abstract
BackgroundNumerous studies have demonstrated limited survival benefits of transarterial chemoembolization (TACE) alone in the treatment of intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria. The advent of immunotherapy, particularly immune checkpoint...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have